加拿大成人侵袭性肺炎链球菌疾病中PCV21(V116)与其它肺炎球菌疫苗血清型覆盖比较及V116独有八种血清型流行病学:SAVE研究2018-2021
SAVE研究2018至2021年收集加拿大5854株侵袭性肺炎链球菌分离株,比较V116与PCV15、PCV20、PPSV23的血清型覆盖。成人中V116覆盖78.9%,高于PCV15的42.7%、PCV20的59.0%和PPSV23的70.4%;V116独有八种血清型占成人分离株19.7%,≥65岁成人中占26.8%。
要点
- 成人IPD分离株V116覆盖78.9%,高于PCV15、PCV20和PPSV23。
- V116独有八种血清型占成人IPD的19.7%,≥65岁成人中占26.8%。
- 八种独有血清型中15A和23A的多重耐药率最高,分别为17.0%和10.2%。
核心结论
- V116对加拿大成人(包括老年人)的IPD分离株覆盖显著(P < 0.05)高于PCV15、PCV20和PPSV23,且覆盖常见耐药表型包括多重耐药。
- V116独有八种血清型在≥65岁患者IPD分离株中所占比例高于较年轻成人。
研究设计与样本
- SAVE研究为加拿大抗菌药物耐药联盟与加拿大公共卫生署-国家微生物实验室合作开展的研究,2018至2021年共收集5854株侵袭性肺炎链球菌疾病分离株。
- 血清型采用Quellung反应确定,抗菌药物敏感性试验采用CLSI肉汤微量稀释法。
主要发现
- 成人(≥18岁)、50-64岁成人和≥65岁成人中,IPD分离株覆盖率分别为:PCV15(42.7%;41.0%,39.8%)、PCV20(59.0%;60.2%,52.2%)、PPSV23(70.4%;75.1%,60.0%)、V116(78.9%;76.3%,81.5%)、V116联合PCV20(92.2%;91.0%,89.3%)。
- V116独有八种血清型分别占成人(≥18岁)和≥65岁成人IPD分离株的19.7%和26.8%。
- 八种独有V116血清型中,15A和23A的多重耐药率最高,分别为17.0%和10.2%;15A分离株中6.7%为广泛耐药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: V116 is a novel 21-valent pneumococcal conjugate vaccine (PCV) intended for use in adults. OBJECTIVES: To estimate current V116 serotype coverage in adult patients in Canada compared with PCV15, PCV20 and PPSV23 vaccines, and to describe isolate demographics for the eight unique serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) covered by V116. METHODS: From 2018 to 2021 inclusive, the SAVE study collected 5854 invasive pneumococcal disease (IPD) isolates as part of a collaboration between the Canadian Antimicrobial Resistance Alliance and the Public Health Agency of Canada-National Microbiology Laboratory. Serotypes were determined by Quellung reaction and antimicrobial susceptibility testing performed using the CLSI broth microdilution method. RESULTS: For adult patients (≥18 years), adults 50-64 years and adults ≥65 years, respectively, IPD isolate coverage was PCV15 (42.7%; 41.0%, 39.8%), PCV20 (59.0%; 60.2%, 52.2%), PPSV23 (70.4%; 75.1%, 60.0%), V116 (78.9%; 76.3%, 81.5%) and V116 plus PCV20 (92.2%; 91.0%, 89.3%). The eight unique V116 serotypes accounted for 19.7% and 26.8% of IPD isolates from adults and adults ≥65 years, respectively. Among the eight unique V116 serotypes, 15A and 23A demonstrated the highest rates of MDR (17.0% and 10.2%, respectively); 6.7% of 15A isolates were XDR. CONCLUSIONS: V116 provided significantly (P < 0.05) greater coverage than PCV15, PCV20 and PPSV23 for adults, including older adults, across all Canadian geographic regions, and against IPD isolates with common antimicrobial resistance phenotypes, including MDR. The eight unique V116 serotypes accounted for a higher proportion of IPD isolate serotypes in patients aged ≥65 years than younger adults.
引用
- Schellenberg JJ, Adam HJ, Baxter MR, et al. Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018-21. J Antimicrob Chemother. 2025. PMID: 40131289. doi:10.1093/jac/dkaf085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。